Evidence map›Paper›PMID 29535050›Full record

ArticleToxicology letters2018

TRPA1 and CGRP antagonists counteract vesicant-induced skin injury and inflammation.

Satyanarayana Achanta, Narendranath Reddy Chintagari, Marian Brackmann, Shrilatha Balakrishna, Sven-Eric Jordt

Abstract read
In one paragraph

Article in Toxicology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Review
  3. Wound Repair and CaCells · 2024
    Review
  4. Article
  5. Article
  6. Inflammation-the role of TRPA1 channel.Frontiers in physiology · 2023
    Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. TRPV1 in Pain and Itch.Advances in experimental medicine and biology · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Satyanarayana AchantaDepartment of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA.
Narendranath Reddy ChintagariDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA.
Marian BrackmannDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA.
Shrilatha BalakrishnaDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06510, USA.
Sven-Eric JordtDepartment of Anesthesiology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: sven.jordt@duke.edu.
Yale University · USDuke University · US

Funding

Targeting Injury Pathways to Counteract Pulmonary Agent and Vesicant ToxicityU01ES015674 · NIEHS · YALE UNIVERSITY · PI JORDT, SVEN-ERIC · 2006 to 2016
$6.0M
NIEHS NIH HHS U01 ES015674
6 · The paper itself

Abstract

The skin is highly sensitive to the chemical warfare agent in mustard gas, sulfur mustard (SM) that initiates a delayed injury response characterized by erythema, inflammation and severe vesication (blistering). Although SM poses a continuing threat, used as recently as in the Syrian conflict, no mechanism-based antidotes against SM are available. Recent studies demonstrated that Transient Receptor Potential Ankyrin 1 (TRPA1), a chemosensory cation channel in sensory nerves innervating the skin, is activated by SM and 2-chloroethyl ethyl sulfide (CEES), an SM analog, in vitro, suggesting it may promote vesicant injury. Here, we investigated the effects of TRPA1 inhibitors, and an inhibitor of Calcitonin Gene Related Peptide (CGRP), a neurogenic inflammatory peptide released upon TRPA1 activation, in a CEES-induced mouse ear vesicant model (CEES-MEVM). TRPA1 inhibitors (HC-030031 and A-967079) and a CGRP inhibitor (MK-8825) reduced skin edema, pro-inflammatory cytokines (IL-1β, CXCL1/KC), MMP-9, a protease implicated in skin damage, and improved histopathological outcomes. These findings suggest that TRPA1 and neurogenic inflammation contribute to the deleterious effects of vesicants in vivo, activated either directly by alkylation, or indirectly, by reactive intermediates or pro-inflammatory mediators. TRPA1 and CGRP inhibitors represent new leads that could be considered for validation and further development in other vesicant injury models.

Indexed as

AcetanilidesAnimalsBiomarkersBlisterCalcitonin Gene-Related PeptideChemical Warfare AgentsCytokinesEar, ExternalKeratinocytesMaleMatrix Metalloproteinase 9MiceMice, Inbred C57BLMustard GasPurinesPyridines2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide2-chloroethyl ethyl sulfideAcetanilidesBiomarkersCalcitonin Gene-Related PeptideChemical Warfare AgentsCytokinesMatrix Metalloproteinase 9MK-8825Mmp9 protein, mouseMustard GasPurinesPyridinesSpiro CompoundsTRPA1 Cation ChannelTrpa1 protein, mouseCEESCGRPMedical countermeasuresMouse ear vesicant model (MEVM)Skin vesicant injurySulfur mustardTRPA1

Identifiers

PMID29535050
PMCPMC5975083
OpenAlexW2790791246

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.